---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-296200"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2026-07-06T20:15:17+00:00"
generated_at: "2026-07-06T20:16:13.057080+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RxSight lowers FY2026 sales guidance, reports Q2 prelim revenue $32-34M, Alcon collaboration

## Summary
- Preliminary Q2 2026 revenue $32-34M, including $5-7M from Alcon collaboration; sales ~$27M (24,917 LAL units, 11 LDD units).
- FY2026 sales guidance lowered to $110-120M (from $120-135M); total revenue guidance $140-160M including collaboration revenue $30-40M.
- Gross margin guidance raised to 73-75% (from 70-72%); operating expense guidance unchanged at $150-160M.
- Strategic collaboration with Alcon to develop light-adjustable presbyopia-correcting IOLs; pipeline includes next-gen LAL, LAL+, LAL Toric.
- Cash and investments ~$209M as of June 30, 2026; cites competitive trialing as headwind.

## SEC filing metadata
- accession: 0001193125-26-296200
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2026-07-06T20:15:17+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000119312526296200/0001193125-26-296200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000119312526296200/rxst-20260706.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-296200
- JSON: https://secwatch.observer/filing/0001193125-26-296200.json
- Plain text: https://secwatch.observer/filing/0001193125-26-296200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.